TABLE IV.

Results of platinum-based agent trials in early and advanced triple-negative breast cancer

Pre-operative
Trial Phase First Author	n	Regimen	pCR (%)	ORR (%)	Median DFS (months)	Median OS (months)
Phase II expansion - subgroup Frasci68	74	Cis + E + Pac with GCSF support	62	98.3	76% (5-year)	89% (5-year)
Phase II Ryan69	51	Cis + Bev	16	80	n/a	n/a
Phase II Silver70	28	Cis	21	64	n/a	n/a
Phase II Gronwald7	25a	Cis	72	100	n/a	n/a
Phase III subgroup Sirohi41	17	Plt + E + F(ci)	17b	100	68	65% (5-year)
Phase II Torrisi71	30	Cis + E + F(ci) → Pac	40	86	87.5% (2-year)	n/a
Advanced
Trial Phase First Author	n	Regimen	ORR (%)		Median PFS (months)	Median OS (months)
Phase III First-line+O’Shaughnessy64	258	Cb + Gem	30		4.1	11.1
Rd Phase II First-line+Baselga BALI-172	58	Cis	10.3		1.5	9.4
Phase II First-line+Kim73	62	Plt	27.6		4.1	10.8
Phase II First-line Wang74	45c	Gem + Cis	62.2		6.2	n/a

^aAll patients had BRCA1 mutation, 20 patients (80%) were TN.

^bpCR rates could not be compared because 65% (11 of 17) of patients within the TN group did not undergo surgery due to CR. One out of six (17%) patients with TN tumors who underwent surgery had a pCR.

^cPreliminary analysis of 45 patients out of 65 enrolled.

Bev = bevacizumab; Cb = carboplatin; ci = continuous infusion; Cis = cisplatin; CR = complete response; DFS = disease-free survival; E = epirubicin; F = fluorouracil; GCSF = granulocyte colony-stimulating factor; Gem = gemcitabine; n = number of patients; n/a = not available; ORR = overall response rate; OS = overall survival; Pac = paclitaxel; pCR = pathological complete response; PFS = progression-free survival; Plt = platinum-based regimens; Rd = randomized; TN = triple-negative; TTP = time to progression